Talazoparib Is Active in gBRcA1/2 Mutation-Positive Early HER2-Negative Breast Cancer
Researchers evaluated the efficacy and safety of talazoparib in the neoadjuvant setting in a phase 2, nonrandomized, single-arm, open-label study.
All articles by Walter Alexander
Age and Stage at Breast Cancer Diagnosis Don’t Account for Racial Disparities in Distant Metastases
Black patients were more likely than White patients to have distant metastases.
Neoadjuvant Nivolumab Plus Relatlimab Produced a High pCR Rate in Stage III-IV Melanoma
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk Melanoma
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
- Loading...
Loading...
Loading... 
Loading...